CDKN2A and CDKN2B methylation in coronary heart disease cases and controls

  • Authors:
    • Jinyan Zhong
    • Xiaoying Chen
    • Huadan Ye
    • Nan Wu
    • Xiaomin Chen
    • Shiwei Duan
  • View Affiliations

  • Published online on: October 16, 2017     https://doi.org/10.3892/etm.2017.5310
  • Pages:6093-6098
0

Abstract

The aim of the present study was to investigate the association between cyclin‑dependent kinase inhibitor 2A (CDKN2A) and cyclin‑dependent kinase inhibitor 2B (CDKN2B) methylation, and coronary heart disease (CHD), and to explore the interaction between methylation status and CHD clinical characteristics in Han Chinese patients. A total of 189 CHD (96 males, 93 females) and 190 well‑matched non‑CHD controls (96 males, 94 females) were recruited for the study. Methylation‑specific polymerase chain reaction technology was used to examine gene promoter methylation status. Comparisons of methylation frequencies between CHD and non‑CHD patients were carried out using the Chi‑square test. Methylation levels of CDKN2A and CDKN2B genes were not found to be associated with the risk of CHD. However, the mean age of CDKN2A‑hypermethylated participants was significantly lower than CDKN2A‑unmethylated participants (58.73±5.88 vs. 62.62±5.36 years, adjusted P<0.001). Conversely, the mean age of CDKN2B‑hypermethylated participants was significantly higher compared with CDKN2B‑unmethylated participants (62.26±5.48 vs. 58.33±7.47 years, adjusted P=0.048). In addition, CDKN2B methylation frequencies were significantly increased in female participants compared with males (99.47 vs. 11.98%, P=0.032). In conclusion, the results indicated that CDKN2A and CDKN2B promoter methylation frequencies were significantly associated with age, and there was a gender dimorphism in CDKN2B methylation.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhong, J., Chen, X., Ye, H., Wu, N., Chen, X., & Duan, S. (2017). CDKN2A and CDKN2B methylation in coronary heart disease cases and controls. Experimental and Therapeutic Medicine, 14, 6093-6098. https://doi.org/10.3892/etm.2017.5310
MLA
Zhong, J., Chen, X., Ye, H., Wu, N., Chen, X., Duan, S."CDKN2A and CDKN2B methylation in coronary heart disease cases and controls". Experimental and Therapeutic Medicine 14.6 (2017): 6093-6098.
Chicago
Zhong, J., Chen, X., Ye, H., Wu, N., Chen, X., Duan, S."CDKN2A and CDKN2B methylation in coronary heart disease cases and controls". Experimental and Therapeutic Medicine 14, no. 6 (2017): 6093-6098. https://doi.org/10.3892/etm.2017.5310